Characteristics and functional outcome of traumatic hyphema without routine administration of epsilon-aminocaproic acid.
BACKGROUND
The prevalence of traumatic hyphema as well as the distribution of its severity varies among different patient populations. Treatment recommendations in the literature differ significantly among various published reports. This lack of a uniformly accepted treatment probably reflects the different characteristics of this pathology among the populations investigated and cells for a population-adjusted treatment recommendation.


OBJECTIVE
To report the characteristics and functional outcome of patients with traumatic hyphema and to discuss possible recommendations regarding the use of epsilon-aminocaproic acid.


METHODS
A prospective, non-randomized study was conducted in 154 consecutive patients with traumatic hyphema, including data collection of ophthalmic status at various time points, the presence or absence of secondary hemorrhage, and final visual acuity.


RESULTS
Of the 154 eyes studied over 3 years, nearly 90% had hyphema of grade 1 or less, 5 (3.25%) experienced rebleeding, and 2 (1.3%)--neither of which rebled--needed surgical intervention. None of the four patients who experienced final visual acuity of 6/40 or less suffered rebleeding.


CONCLUSIONS
The use of epsilon-aminocaproic acid in the studied population was unjustified and routine use of epsilon-aminocaproic acid in our patient population is probably not indicated. A treatment policy regarding epsilon-aminocaproic acid use should be adjusted to the population being treated.
Beiran
Itzchak
I
Department of Ophthalmology, Rambam Medical Center, Haifa, Israel. i_beiran@rambam.health.gov.il
Talmon
Tamar
T
Miller
Benjamin
B
D000293:Adolescent; D000328:Adult; D015119:Aminocaproic Acid / Q000627:therapeutic use*; D000933:Antifibrinolytic Agents / Q000627:therapeutic use*; D002648:Child; D005130:Eye Hemorrhage / Q000209:etiology; D006801:Humans; D006988:Hyphema / Q000145:classification / Q000150:complications / Q000188:drug therapy*; D011446:Prospective Studies; D012720:Severity of Illness Index; D016896:Treatment Outcome
D000933:Antifibrinolytic Agents; D015119:Aminocaproic Acid